Hot meetings x 3! FDA Microbiome AdComm, Diagnostic devices, ASM-ESCMID developer meeting

Dear All, I think it’s worth a newsletter to call your attention to several upcoming meetings. In addition to the 30 Aug CDC-FDA webinar on “Drug Development Considerations for the Prevention of Healthcare-Associated Infections” and PACCARB’s 12-13 Sep 2022 pandemic wargaming event, we have these 3 meetings. The first two just now hit my radar and the 3rd is worth a shout-out: 

  • 15 Sep 2022 (virtual, 2-4p ET): Duke-Margolis webinar entitled “Advancing Bacterial Diagnostic Development.”
    • Mark McClellan’s team at Duke-Margolis consistently assembles instructive webinars and this one will focus on strategies for regulatory clearance of new diagnostics. Don’t miss it!
    • Go here for more details and to register.
  • 22 Sep 2022 (virtual, 8.30-5.00p ET): FDA Advisory Committee discussing an application for approval of Rebyota (Fecal Microbiota, Live) with a requested indication to “reduce the recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent Clostridioides difficile infection.”
  • 4-7 Oct 2022 (Dublin, Ireland): The 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.
    • This series has been one of my favorite meetings since its start … this year it is back and in-person.
    • The scientific program looks excellent and the meeting has lots of opportunity for networking. 
    • I strong encourage attendance! Go here for all the details..

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Share

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Mitigating environmental AMR: Grants from ICARS

Dear All, Our colleagues at ICARS have just announced a fascinating grant opportunity focused on environmental AMR. They don’t want surveillance — they want research on to how to intervene! Excerpting from their website: ICARS seeks “projects to mitigate the evolution and transmission of resistance in the natural or built environment”. Proposals are expected to

Casting call: Lifeline (Sir Alexander Fleming, the musical)

Dear All, I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City NY! The deadline to

Scroll to Top